Meeting
2019 ASCO Annual Meeting
Real-world treatment patterns and outcomes in ER+/PR+/HER2+ metastatic breast cancer (MBC) patients: A National Cancer Database analysis.
Authors
Abby Statler
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
Abby Statler , Zeina A. Nahleh , Brian Hobbs , Wei (Auston) Wei , Annie Gupta , Cassann N. Blake
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1033)
DOI
10.1200/JCO.2019.37.15_suppl.1033
Abstract #
1033
Poster Bd #
114
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Treatment patterns and their impact on the outcome of patients with HR+/HER2+ metastatic breast cancer in a large real-world cohort.
First Author: Marcela Carausu
Poster
2022 ASCO Annual Meeting
Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience.
First Author: Chris Labaki
Poster
2020 ASCO Virtual Scientific Program
Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2+/HR+ metastatic breast cancer.
First Author: Matthew Loft
Poster
2019 ASCO Annual Meeting
Disparities in treatment patterns and overall survival (OS) in hormone receptor-positive HER2+ metastatic breast cancer (MBC): A National Cancer Database Analysis.
First Author: Abby Statler